Chitosan: A promising therapeutic agent and effective drug delivery system in managing diabetes mellitus. (1st November 2020)

• Record Type: Journal Article
• Authors: Sarkar, Sanjib; Das, Dibyendu; Dutta, Prachurjya; Kalita, Jatin; Wann, Sawlang Borsingh; Manna, Prasenjit
• Is Part Of: Carbohydrate polymers. Volume 247(2020)
• Publication Date: 2020-11-01
• Subjects: ACAT acyl-CoA cholesterol transferase -- ACC acetyl-CoA carboxylase -- ACD amphiphilic chitosan derivatives -- ADRP adipose differentiation-related protein -- AMP adenosine monophosphate -- AMPK AMP-activated kinase -- AOX1 aldehyde oxidase 1 -- ASBT apical sodium-bile acid transporter -- C/EBPα CCAAT-enhancer binding protein α -- CETP Cholesteryl ester transfer protein -- CS chitosan -- CS/TPP/insulin chitosan-tripolyphosphate-insulin -- CPPs cell-penetrating peptides -- CS/gPGA NPs chitosan and poly(g-glutamic acid) nanoparticles -- CS/b-Gp chitosan/b-glycerol phosphate -- Cyp7A1 cytochrome P450 7A1 -- DM diabetes mellitus -- DPP-4 dipeptidyl peptidase-4 -- EDTA ethylenediaminetetraacetic acid -- EICSCN enteric coated insulin-chitosan complex nanoparticles -- FABP 4 fatty acid-binding protein 4 -- FAS fatty acid synthase -- FATP1 fatty acid transporter protein 1 -- GA glutaraldehyde -- GLP-1 Glucagon-like peptide 1 -- Gly glycine -- GLUT4 glucose transporter-4 -- HDL high density lipoprotein -- HF high fat -- HP-β-CD hydroxypropyl-β-cyclodextrin -- HbA1c haemoglobin A1c -- HMGCR 3-Hydroxy-3-Methylglutaryl-CoA Reductase -- ICSN insulin loaded chitosan nanoparticles -- ICSCN insulin chitosan complex nanoparticles -- IBABP ileal bile acid binding protein -- IL6 interleukin 6 -- LDL low-density lipoprotein -- LPL lipoprotein lipase -- LXRs liver X receptors -- L/C NPs lecithin/chitosan nanoparticles -- LMCS low molecular weight chitosan -- mPEG-PLGA CS NPs monomethoxy (polyethylene glycol)-poly (lactide-co-glycolic acid) chitosan nanoparticles -- mPEG-PLGA AL NPs monomethoxy (polyethylene glycol)-poly (lactide-co-glycolic acid) alginate nanoparticles -- NIDDM non-insulin-dependent diabetes mellitus -- NTS nucleus of the solitary tract -- P poloxamer -- PPARα peroxisome proliferator-activated receptor α -- PSi porous silicon nanoparticles -- γ-PGA poly(γ-glutamic acid) -- PKC Protein kinase C -- PLGA poly(lactic-co-glycolic acid) -- PEPCK phosphoenolpyruvate carboxykinase -- SREBP1c sterol regulatory element-binding protein 1c -- STZ streptozotocin -- T1D type 1 diabetes -- T2D type 2 diabetes -- TMC-Cys trimethylchitosan-cysteine -- TMC N-trimethyl chitosan -- TNFα tumour necrosis factor α -- TPP tripolyphosphate -- VLDL-cholesterol very low density lipid-cholesterol -- ZDF Zucker Diabetic Fatty; Alginate -- Chitosan -- Chitooligosaccharide -- Cholic acid -- Glutaraldehyde -- Polyethylene glycol -- Poly(lactic-co-glycolic acid) -- Poly(g-glutamic acid) -- Trimethylchitosan -- Tripolyphosphate; Chitosan -- Impaired glucose and lipid metabolism -- Diabetes mellitus -- Chitosan-based micro/nano-carriers -- Antidiabetic drug delivery; Polysaccharides -- Periodicals; Polysaccharides -- Periodicals; Polysaccharides -- Périodiques; Electronic journals; 547.78
• DOI: 10.1016/j.carbpol.2020.116594
• Languages: English
• ISSNs: 0144-8617

Abstract

Graphical abstract: Highlights: Chitosan has attracted scientific attention for treating diabetes mellitus (DM). Chitosan can recover impaired insulin secretion and glucose metabolism linked with DM. Chitosan supplementation can improve altered lipid metabolism associated with DM. Chitosan-based micro/nano vehicles have been used to deliver anti-diabetic drugs. Chitosan can be used as therapeutic agent and drug carrier for treating DM. Abstract: Chitosan, a promising carbohydrate biopolymer is gaining scientific attention in a wide range of biomedical applications due to its outstanding chemical and pharmacokinetic properties. Recently, various studies have demonstrated the beneficial activities of chitosan in protecting and proliferating pancreatic beta cells, lowering hyperglycemia, and preventing impaired lipid metabolism associated diabetes mellitus. Moreover, chitosan has also been used in formulating several types of micro/nano-carriers for the delivery of different antidiabetic drugs, like insulin, GLP1, exendin-4, DPP-4 inhibitor, and plasmid encoding insulin or GLP to reduce hyperglycemia. This review for the first time provides an overview of the currently available evidences on the potential benefits of chitosan in managing diabetes mellitus and also emphasizes on the chitosan-based micro/nano-carriers in delivery of various antidiabetic drugs via oral, nasal, and subcutaneous routes. The outcome of this review will be helpful for the development of a novel therapeutic to achieve better control of diabetes mellitus.